Enhancement of implantable glucose sensor function in vivo using gene transfer-induced neovascularization

Klueh, Ulrike; Dorsky, David I.; Kreutzer, D. L.

doi:10.1016/j.biomaterials.2004.04.017

Cited by 79 publications

(79 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Functioning glucose sensors that release VEGF are under development. Similarly, Klueh et al have genetically engineered cells to overexpress VEGF and then incorporated these cells in an electrochemical glucose sensor based on an ova-chorioallantoic membrane (43). In this design, the immobilized cells produce VEGF at the site of glucose-sensor implantation and thereby increase angiogenesis at the site of the inflammatory response.…”

Section: Improving Biocompatibility Of Subcutaneous Sensorsmentioning

confidence: 99%

In Vivo Chemical Sensors: Tackling Biocompatibility

Frost¹,

Meyerhoff²

2006

Anal. Chem.

134

132

View full text Add to dashboard Cite

Section: Improving Biocompatibility Of Subcutaneous Sensorsmentioning

confidence: 99%

In Vivo Chemical Sensors: Tackling Biocompatibility

Frost¹,

Meyerhoff²

2006

Anal. Chem.

134

132

View full text Add to dashboard Cite

“…29 The latter is known to extend sensor performance and shorten the time lag. 16 For this reason, we opted to modify the surface of the packaging material with the aim of increasing the vessel density at the implantation site.…”

Section: Why Apply Biomaterials Surface Modification?mentioning

confidence: 99%

First step toward near-infrared continuous glucose monitoring: in vivo evaluation of antibody coupled biomaterials

Gellynck

Kodeck

Walle

et al. 2014

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Continuous glucose monitoring (CGM) is crucial in diabetic care. Long-term CGM systems however require an accurate sensor as well as a suitable measuring environment. Since large intravenous sensors are not feasible, measuring inside the interstitial fluid is considered the best alternative. This option, unfortunately, has the drawback of a lag time with blood glucose values. A good strategy to circumvent this is to enhance tissue integration and enrich the peri-implant vasculature. Implants of different optically transparent biomaterials (poly(methyl-methacrylate) [PMMA] and poly(dimethylsiloxane) [PDMS]) -enabling glucose monitoring in the near-infrared (NIR) spectrum -were surface-treated and subsequently implanted in goats at various implantation sites for up to 3 months. The overall in vivo biocompatibility, tissue integration, and vascularization at close proximity of the surfaces of these materials were assessed. Histological screening showed similar tissue reactions independent of the implantation site. No significant inflammation reaction was observed. Tissue integration and vascularization correlated, to some extent, with the biomaterial composition. A modification strategy, in which a vascular endothelial-cadherin antibody was coupled to the biomaterials surface through a dopamine layer, showed significantly enhanced vascularization 3 months after subcutaneous implantation. Our results suggest that the developed strategy enables the creation of tissue interactive NIR transparent packaging materials, opening the possibility of continuous glucose monitoring.

show abstract

“…While many cytokines exist, vascular endothelial growth factor (VEGF) has appeared in the greatest number of glucose sensor papers. 35,[54][55][56][57][58][59] Increased amounts of localized VEGF has been shown to promote angiogenesis in surrounding tissue. 60 Upregulation of VEGF in a chick chorioallantoic membrane model provided enhanced glucose sensor response compared with controls, exemplifying the usefulness of VEGF for in vivo biosensors.…”

Section: Active Releasementioning

confidence: 99%

“…60 Upregulation of VEGF in a chick chorioallantoic membrane model provided enhanced glucose sensor response compared with controls, exemplifying the usefulness of VEGF for in vivo biosensors. 57 Surfaces that release VEGF have been shown to improve vascularity of the surrounding tissue. 35,[54][55][56][57][58][59]61 However, VEGF does not address other problems related to the FBR and may even increase the inflammatory response.…”

Section: Active Releasementioning

confidence: 99%

“…57 Surfaces that release VEGF have been shown to improve vascularity of the surrounding tissue. 35,[54][55][56][57][58][59]61 However, VEGF does not address other problems related to the FBR and may even increase the inflammatory response. 35 Rather than increasing vascularity, anti-inflammatory drugs may reduce the FBR and represent potential active release agents from glucose sensor coatings.…”

Section: Active Releasementioning

confidence: 99%

See 1 more Smart Citation

Glucose Sensor Membranes for Mitigating the Foreign Body Response

Koh

Nichols

2011

J Diabetes Sci Technol

View full text Add to dashboard Cite

Continuous glucose monitoring devices remain limited in their duration of use due to difficulties presented by the foreign body response (FBR), which impairs sensor functionality immediately following implantation via biofouling and leukocyte infiltration. The FBR persists through the life of the implant, culminating with fibrous encapsulation and isolation from normal tissue. These issues have led researchers to develop strategies to mitigate the FBR and improve tissue integration. Studies have often focused on abating the FBR using various outer coatings, thereby changing the chemical or physical characteristics of the sensor surface. While such strategies have led to some success, they have failed to fully integrate the sensor into surrounding tissue. To further address biocompatibility, researchers have designed coatings capable of actively releasing biological agents (e.g., vascular endothelial growth factor, dexamethasone, and nitric oxide) to direct the FBR to induce tissue integration. Active release approaches have proven promising and, when combined with biocompatible coating materials, may ultimately improve the in vivo lifetime of subcutaneous glucose biosensors. This article focuses on strategies currently under development for mitigating the FBR.

show abstract

Enhancement of implantable glucose sensor function in vivo using gene transfer-induced neovascularization

Cited by 79 publications

References 35 publications

In Vivo Chemical Sensors: Tackling Biocompatibility

In Vivo Chemical Sensors: Tackling Biocompatibility

First step toward near-infrared continuous glucose monitoring: in vivo evaluation of antibody coupled biomaterials

Glucose Sensor Membranes for Mitigating the Foreign Body Response

Contact Info

Product

Resources

About